Inspira Technologies CEO Issues Letter to Shareholders Emphasizing Strategic Transformation

Inspira Technologies issued a letter to its shareholders from its CEO, Dagi Ben-Noon. The company said, "The past several months have marked a defining period in our Company's evolution. We have taken decisive steps to reshape Inspira around a sharper strategic focus, a stronger asset base, and multiple near-term and long-term pathways to shareholder value creation. This letter is intended to clearly outline where we are heading, why we believe this moment is important, and how our Additively Manufactured Electronics platform, quantum connectivity strategy, and medical business each contribute to a broader plan to convert our assets into measurable value. Our strategy is built around three distinct value tracks: a commercially active AME platform, a focused quantum connectivity program targeting one of the industry's most important scaling bottlenecks, and a medical business being positioned as a wholly owned subsidiary with meaningful near-term strategic potential. Each track has its own timeline, execution path, and value driver. Together, they form a coordinated framework designed to convert the Company's assets into measurable business outcomes and long-term shareholder returns. Importantly, our recent commercial activity should not be viewed as an isolated event, but as clear evidence of a broader revenue ramp now developing across the Company. This ramp up is expected to be supported by AME system sales, recurring consumables and service revenues, and continued monetization of our medical technologies. Our objective is to convert this commercial activity into a scalable revenue base that grows consistently quarter over quarter. This revenue ramp will be reflected in the Company's upcoming financial reports. At the same time, the Company's management has actively reduced the burn rate of the legacy medical business while reallocating capital toward the AME platform and quantum connectivity program. This is not a passive increase in expenses; it is a deliberate shift in the Company's cost structure from legacy medical operating expenses toward commercial AME execution, quantum development, customer deployments, and revenue-generating activity. Our execution priorities are clear: accelerate cash collection, expand recurring revenue, improve gross margins, increase capital efficiency, and convert commercial activity into scalable revenue growth... Looking ahead, we believe Inspira is at an inflection point. The convergence of an actively scaling AME commercial platform, a quantum connectivity strategy targeting one of the largest emerging hardware markets in technology, and a medical monetization process designed to deliver non-dilutive capital, creates what we believe is a unique combination of near-term commercial visibility and long-term strategic upside. We expect the coming weeks and months to bring continued execution milestones across all three tracks. On behalf of the entire team, thank you for your continued support and confidence. We are committed to executing this strategy with discipline, transparency, urgency, and a clear focus on measurable milestones. Our priority is to translate the Company's assets, strategic partnerships, and commercial progress into concrete results for our shareholders."